Viatris Inc.
Company Snapshot
Founded: 2020
Entity Type: Public
Employees: 30,000
Region: North America and Europe
Revenue: $14,299.9 Millions
Revenue Year: 2025
Headquarter: Pennsylvania, U.S.
Key Geographics: North America, Europe, Asia-Pacific, Rest of the World
Corporate Address: 1000 Mylan Blvd., Canonsburg, PA 15317, U.S. Tel. +1-724-514-1800 www.viatris.com
Company Overview
Viatris Inc., a global pharmaceutical company, was formed in November 2020 by merging Mylan N.V. and Pfizer Inc.’s Upjohn division. It operates across numerous countries with a diverse portfolio of generic drugs and biosimilars. The company operates its business through three main segments: brands, generics and others.
Financial Highlights (FY 2025)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Viatris Inc. In News
Company's Business Segments
- Brands : This segment focuses on well-known, globally recognized branded and legacy medicines such as Lipitor, Norvasc, Caduet, Inspra, Nitrostat, Revatio, Dilatin, Lyrica, Neurontin, and Relpax.
- Generics : This segment provides standard and complex generic medications such as Wixela, Inhub, ADVAIR DISKUS, Glatiramer acetate injection, and Copaxone.
Applications/End User Industries
- Governments
- Healthcare Providers
- Consumer
- Pharmaceuticals
- Technology Partners and Patients
- Life Sciences